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Modeling sporadic alzheimer's disease: the insulin resistant brain
state generates multiple long-term morphobiological
abnormalities inclusive hyperphosphorylated tau protein and
amyloid-beta. A Synthesis
Abstract
Nosologically, Alzheimer's disease (AD) is not a single disorder. Missense gene mutations involved in
increased formation of the amyloid-beta protein precursor derivatives amyloid-beta
(Abeta)<formula>_{1-40}</formula> and Abeta<formula>_{1-42/43}</formula> lead to autosomal
dominant familial AD, found in the minority of AD cases. However, millions of subjects suffer from
sporadic AD (sAD) of late onset, for which no convincing evidence suggests Abeta as the primary
disease-generating compound. Environmental factors operating during pregnancy and postnatally may
affect susceptibility genes and stress factors (e.g., cortisol), consequently affecting brain development
both structurally and functionally, causing disorders becoming manifest late in life. With aging, a
desynchronization of biological systems may result, increasing further brain entropy/declining
criticality. In sAD, this desynchronization may involve stress components, cortisol and noradrenaline,
reactive oxygen species, and membrane damage as major candidates causing an insulin resistant brain
state with decreased glucose/energy metabolism. This further leads to a derangement of ATP-dependent
cellular and molecular work, of the cell function in general, as well as derangements in the endoplasmic
reticulum/Golgi apparatus, axon, synapses, and membranes, in particular. A self-propagating process is
thus generated, including the increased formation of hyperphosphorylated tau-protein and Abeta as
abnormal terminal events in sAD rather than causing the disorder, as elaborated in the review.
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Abstract. Nosologically, Alzheimer’s disease (AD) is not a single disorder. Missense gene mutations involved in increased
formation of the amyloid-β protein precursor derivatives amyloid-β (Aβ)1−40 and Aβ1−42/43 lead to autosomal dominant
familial AD, found in the minority of AD cases. However, millions of subjects suffer from sporadic AD (sAD) of late onset,
for which no convincing evidence suggests Aβ as the primary disease-generating compound. Environmental factors operating
during pregnancy and postnatally may affect susceptibility genes and stress factors (e.g., cortisol), consequently affecting brain
development both structurally and functionally, causing diseases that only manifest late in life. With aging, a desynchronization of
biological systems may result, increasing further brain entropy/declining criticality. In sAD, this desynchronization may involve
stress components, cortisol and noradrenaline, reactive oxygen species, and membrane damage as major candidates causing an
insulin resistant brain state with decreased glucose/energy metabolism. This further leads to a derangement of ATP-dependent
cellular and molecular work, of the cell function in general, as well as derangements in the endoplasmic reticulum/Golgi apparatus,
axon, synapses, and membranes, in particular. A self-propagating process is thus generated, including the increased formation of
hyperphosphorylated tau-protein and Aβ as abnormal terminal events in sAD rather than causing the disorder, as elaborated in
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INTRODUCTION
After the German pathologist Rudolf Virchow
(1821–1902) established cellular pathology as the prin-
ciple to determine the causation of a disease, it has be-
come a common feature in medicine to form nosolog-
ical entities of diseases. With respect to Alzheimer’s
disease (AD), this neurodegenerative disorder has not
been found to form a nosological entity.
A very small proportion of 455 families world-
wide (by January 2008) is suffering from AD caused
by missense mutations in the preseniline gene 1
on chromosome 14 (361 families, ∼79.3%), in the
preseniline gene 2 on chromosome 1 (18 families,
∼4.0%), and in the amyloid-β protein precursor
(AβPP) gene on chromosome 21 (76 families,∼16.7%)
(http://www.molgen.ua.ac.be/ADMutations), leading
to autosomal dominant familial AD with an early on-
set. These currently known three mutations are in-
volved in both the overexpression and the abnormal
cleavage of AβPP and the increased formation of the
AβPP derivative amyloid-β (Aβ1−40; Aβ1−42/43) [1],
a keystone for the “amyloid hypothesis” [2], alterna-
tively termed “Aβ hypothesis” [3]. Numerous experi-
ments, using transfected cells in culture [3] and trans-
genic animals [4] to model this form of AD, clear-
ly demonstrated the amyloidotic process of hereditary
AD followed by other neuropathological changes as
downstream consequences of abnormal Aβ accumu-
lation [2]. It is common to all these studies that the
amyloid-relevant gene mutations are exclusively the
inevitable starting point of the pathological processes
relevant to hereditary AD [5].
In contrast, in sporadic AD, which approximately
15 million people worldwide suffer from [6], no such
mutations were found as yet, i.e., the mutation-related
stimulus of the permanent and increased formation of
Aβ is lacking. Thus, the role of the latter in the cau-
sation of sporadic AD remains enigmatic [7,8], all the
more so since the brains, in the course of time, of longi-
tudinally examined aged nondemented cognitively nor-
mal subjects have been found to contain abundant neu-
ritic plaques and neurofibrillary tangles [9–11]. Also,
the decline in mental status followed over several years
was demonstrated not to be accompanied by changes
in the numerical density of plaques and tangles [12–
14]. Finally, it was the neuronal loss in the association
areas rather than the neuritic plaques and neurofibril-
lary tangles that directly contributed to cognitive dam-
age [15]. In a most recent study on postmortem brains
of patients who underwent Aβ42 immunization over
84 weeks, a marked reduction of amyloid plaques was
found [16]. However, this clearance did not prevent the
progression of dementia and severe end-stage dementia
before death. Otherwise, age has been found to be the
leading risk factor for sporadic AD [17,18]. However,
additional factors beside the aging process itself may
be necessary to generate this form of AD [19]. In this
context, susceptibility genes have been demonstrated
to participate in the causation of disorders becoming
evident late in life, inducing a chronic and progres-
sive course (e.g., apoliprotein E4 (APOE4) and insulin
degrading enzyme (IDE).
With respect to sporadic AD, two clearly defined
susceptibility genes may be of great functional interest:
1) A single nucleotide polymorphism has recently
been found in the gene coding for 11β-hydroxysteroid
dehydrogenase I, which is associated with a 6-fold in-
creased risk for sporadic AD [20]. In the brain, 11β-
hydroxysteroid dehydrogenase I predominantly acts as
a reductase which reduces cortisone to the active hor-
mone cortisol, thus amplifying the glucocorticoid ac-
tion [21]. Additionally, haplotypes of the glucocorti-
coid receptor gene were found to be associated with
an impaired hypothalamic-pituitary-adrenal (HPA) ax-
is function in late life, affecting the regulation of the
glucocorticoid receptor gene [22,23].
Environmental factors operating early in life dur-
ing terminal pregnancy and in the following postna-
tal period affect brain development, altering its struc-
ture and function throughout life (programming of the
brain) [24–30], may result in age-associated disor-
ders [31]. Among the parameters involved is the HPA-
axis, demonstrating a persistent hyperactivity [32,33]
mediated by cortisol. During normal development, the
granule cell layer of the dentate gyrus has been shown
to be the site of neurogenesis and cell migration [34].
Postnatal application of cortisol caused an inhibition
of the proliferation of granule cells [35] and affect-
ed cell division [36]. Also, prenatal stress in the last
week of pregnancy in rats induced lifespan reduction in
neurogenesis in the dentate gyrus, accompanied with
learning deficits [37]. A cumulative lifetime expo-
sure to glucocorticoid hormones was found to decrease
neurogenesis in the dentate gyrus along with cognitive
deficits [38]. Beside these direct glucocorticoid effects
on the dentate gyrus, it may also cause insulin receptor
dysfunction in terms of insulin resistance and diabetes
mellitus type 2 later in life [39,40].
2) Allelic abnormalities of the APOE4 gene on chro-
mosome 19 affect lipid transport in the brain. It is
involved in the delivery and clearance of the plasma
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membrane constituent cholesterol, and thus in the state
and function of plasma membranes [41,42]. In con-
trast to other isoforms, APOE4 is less protective against
cell damage and has poor repair qualities, e.g., against
hydrogen superoxide-induced damage [43,44]. The
multitude of physiological functions and their conse-
quences after damage due to sporadic AD have been
detailed elsewhere [45].
A recently published longitudinal study of more than
2,000 participants starting at 50 years of age showed
dementia in around 400 persons 32 years later, 102 of
whom developed pure AD. The latter subjects showed
impaired acute insulin response at midlife, which may
indicate an increased risk for AD [46]. Taken togeth-
er, the above findings may point to distinct metabol-
ic candidates and processes other than Aβ generat-
ing sporadic AD over a longer period of time [47,
48]. These processes may include the neuronal glu-
cose/energy metabolism and its control by the insulin
signal transduction cascade. It is tempting to speculate
that this abnormality is the result of an age-related pro-
cess, starting with a derangement in the programming
of the brain early in life, and developing a desynchro-
nization of complex systems with aging (see below).
Therefore, this synthesis will focus on the physiology
and pathophysiologyof brain glucose/insulin pathways
to prove the hypothesis forwarded in 1998 that sporadic
AD is the brain type of non-insulin dependent diabetes
mellitus [49].
THE NORMAL BRAIN
Glucose metabolism
It is well documented that in the normal mature mam-
malian brain oxidative glucose/energy metabolism is
largely under the control of the neuronal insulin signal
transduction cascade (Figs 1 and 2) [50–52], forming
the basis for both the undisturbed structure and function
of the brain. From the glucose metabolite fructose-6-
phosphate, UDP-N acetylglucosamine (UDP-GlcNAc)
is formed and used for protein 0-glycosylation [53].
The metabolite acetyl-CoA is the source of the gen-
eration of 1) the neurotransmitter acetylcholine [54,
55], necessary for learning and memory processes,
which has also been found to regulate regional cere-
bral blood flow [56], and 2) the membrane constituent
cholesterol in the 3-hydroxy-3-methyl-glutaryl-CoA
cycle [57]. The glucose metabolism-derived energy-
rich compound adenosine triphosphate (ATP) is essen-
tial to most cellular and molecular activities (Fig. 2). A
hierarchy of ATP-utilizing processes has been proposed
in the following order: protein synthesis> RNA/DNA
synthesis > Na+ cycling > Ca2+ cycling > proton
leak. The position in this hierarchy may be determined
by the sensitivity of each process to changes in energy
charge [58–60]. More specifically, and in context with
this article, highly ATP-dependent processes are:
– sorting, folding, transport and degradation of pro-
teins [50,52,61];
– maintenance of pH 6 in the endoplasmic reticu-
lum/Golgi apparatus [62,63];
– heat shock protein-guided transport across the lat-
ter compartments [64–67];
– axonal transport of proteins (1 ATP is needed to
transport a protein over a distance of 8 nm) [68];
– regulation of the conformational state of the insulin
degrading enzyme [69];
– maintenance of intra/extracellular ion homeosta-
sis [70];
– maintenance of biophysical membrane proper-
ties [71];
– regulation of the synaptic membrane phospholi-
pase A2 [72];
– maintenance of synaptic transmission [52,73]; and
– metabolism of both tau-protein (Fig. 1) [74,75]
and AβPP thereafter.
Insulin/insulin receptor
Substantial evidence has been gathered in support of
the presence of both insulin and insulin receptors (IR)
in the brain, as well as of insulin action. The pancreas
is the main source of brain insulin, crossing the blood-
brain barrier by a saturable transport process [76]. A
smaller proportion of insulin is produced in the brain
itself [51,77], starting in immature neuronal cells [78]
and expressed more strongly in neuronal,but not in glial
cells of the mature brain [79]. IR have been found to
be widely dispersed throughout the brain with variable
densities in different brain areas, the highest ones found
in the olfactory bulb, hypothalamus, cerebral cortex,
and hippocampus [80]. Nerve terminals show enriched
densities of IR [81]. Two different types of IR have
been found in the adult mammalian brain: 1) a periph-
eral type on glial cells, and 2) a neuron-specific brain
type with high concentrations on neurons [82]. The
major molecular structure and most of the biochem-
ical properties of neuronal IR have been demonstrat-
ed to be indistinguishable from those in non-nervous
tissues [83].
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Fig. 1. Far-reaching consequences of the neuronal insulin receptor signaling cascade impairment. In physiological conditions insulin binding
induces autophosphorylation of insulin receptor (IR) tyrosine (Tyr) residues and consequently IR-tyrosine kinase (TK) activity, which then
activates downstream signaling cascades. Inhibition of IR-TK activity may be rapidly induced by phosphotyrosine phosphatase (PTP), which
removes phosphate (P) from IR phosphotyrosine. IR responsiveness to insulin may be impaired by PTP dysfunction or by phosphorylation of
IR serine/threonine residues (Ser/Thr). The latter could result from increased glucocorticoid and/or noradrenaline/adrenaline levels. IR signaling
impairment triggers a chain reaction which induces signaling impairments at the level of insulin receptor substrate (IRS) and downstream
signaling pathways, like in the phosphatydilinositol 3 kinase (PI3-K) pathway. In physiological conditions, IR signaling activates PI3-K, which
phosphorylates and by that activates protein kinase B (Akt/PKB). Akt/PKB is involved in (i) glucose/energy metabolism regulation and by that
ATP generation, (ii) insulin degrading enzyme (IDE) activity regulation, and also in (iii) phosphorylation and by that inactivation of glycogen
synthase kinase 3α/β (GSK-3 α/β). IR signaling impairment-induced PI3-K dysfunction leads to reduced Akt/PKB activity, which results
in decreased glucose/energy metabolism and decreased ATP production, compromising all ATP-dependent processes and increasing oxidative
stress, which may include IDE activity regulation and favorisation of tau protein phosphorylation, as well as oxidative stress development.
Glucose metabolism also participates in posttranslational protein modification involving the hexosamine biosynthetic pathway, which leads to
the generation of O-N-acetylglycosamine (O-GlcNAc). O-GlcNAcylation of proteins is proposed to compete with protein phosphorylation,
and in conditions of decreased intraneuronal glucose metabolism O-GlcNAcylation is decreased, which consequently leads to increased protein
phosphorylation, including tau hyperphosphorylation. Additionally, PI3-K dysfunction leads to reduced GSK-3alpha/beta phosphorylation, and
by that GSK-3 α/β activation, leading to phosphorylation of tau protein and intraneuronal Aβ accumulation. Dashed lines/arrows represent
reduction or inhibition of the processes while solid lines/arrows represent stimulation of the processes.
Different mechanisms have been shown to regulate
the IR activity (Fig. 1). Binding of insulin to the IR first
induces autophosphorylation of its tyrosine residues to
activate phosphotyrosine kinase. Dephosphorylation
and consequential inactivation of the IR is performed
by phosphotyrosine phosphatases [84,85]. At the same
time, the reactive oxygen species (ROS) hydrogen per-
oxide (H2O2) is generated by insulin stimulation [86]
occurring under physiological conditions [87,88]. In
case of insulin action, the major target of H2O2 is phos-
photyrosine phosphatase [89], whose activity is tran-
siently and reversibly inhibited to enhance the activi-
ty of phosphotyrosine kinase, and, thus, initiate down-
stream protein phosphorylation in the early insulin ac-
tion cascade [90,91]. Beside H2O2, glucocorticoids
have been found to influence both IR synthesis and its
responsiveness to insulin [92–94]. At the structural lev-
el, glucocorticoids have been shown to alter the branch-
ing of carbohydrate side chains, the size of polyman-
nose chains, and the sialysation of the IR [95], caus-
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Fig. 2. Sequences of disturbances in brain glucose metabolism induced by the neuronal insulin receptor signaling in sporadic AD. Impaired IR
signaling in sporadic AD (sAD) leads to reduced brain glucose metabolism, resulting in a diminished formation of UDP-N-acetylglucosamine
(UDP-GlcNAc), and thus diminished protein O-GlcNAcylation, favoring hyperphosphorylation of tau protein (a). The decrease in acetyl-CoA
leads to the diminished formation of acethylcholine (b). Also, the concentration of tricarboxylic acid (TCA)-cycle constituents is reduced, except
for succinate and malate, which increase by a supply of ketone bodies (anaplerotic reaction) to reduce the glucose-born energy deficit (c). The
concentration of ATP is about 20% lower than normal at the beginning of sAD and detoriates further in the course of the disease, which may lead
to decreased mitochondrial membrane potential and increased oxidative stress (OS) (d).
ing IR desensitization [96], particularly by functional
inhibition of its tyrosine residues [39].
Finally, catecholamines may desensitize the IR by
phosphorylation of its serine/threonine residues [97],
as discussed in detail below.
Insulin degrading enzyme
The gene of IDE, an evolutionary conserved pro-
tein, maps on chromosome 10q. There is evidence of
a linkage near or within the IDE gene and sporadic
AD [98–100].However, no clear mutation in the IDE
gene has been found as yet. IDE mRNA increases from
the first postnatal week to adulthood, to achieve high
levels in the brain thereafter [101]. IDE levels have
been shown to be regulated by the insulin receptor sig-
naling pathway via a phosphatidyl inositol 3-kinase-
dependent mechanism [102].
IDE is a cytosolic metalloendoprotease which has
been implicated in insulin degradation within the
cell [103,104]. Beside insulin, IDE degrades different
groups of substrates according to the Michaelis Men-
ton constant Km. Insulin, transforming growth fac-
tor α, atrial natriuretic peptide, and insulin-like growth
factor II (IGF-2) are high-affinity substrates with Km
∼0.1µM. In contrast, substrates such as glucagon, epi-
dermal growth factor, insulin-like growth factor I (IGF-
1), β-endorphin, and Aβ analogues show lower affinity
at Km >2 µM [105]. The control of IDE may be as-
sumed to be a complex mechanism. The IDE level has
been shown to be regulated by the IR signaling pathway
via a phosphatidyl inositol 3-kinase- dependent mech-
anism [102]. Its catalytic activity has been found to be
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regulated by intracellular long-chain fatty acids (C16–
C20) and by hydrogen peroxide [106]. It is tempting to
assume a concerted action between this ROS species on
the transient inhibition of phosphotyrosinephosphatase
activity and the reduction of IDE activity, which may
both enhance the effect of the insulin cascade (see also
above). The role of ATP is a matter of dispute: 1)
ATP has been reported to show IDE inhibitory effects
on insulin degrading activity [107]; 2) Otherwise, ATP
can increase the rate of cleavage of small peptide sub-
strates of IDE (Fig. 1) [108]. Structurally, IDE can
show two conformational states, termed “open” and
“closed”. In the closed state, IDE cannot bind sub-
strates but it degrades the substrate entrapped in the cat-
alytic chamber. In contrast, in the open state, IDE can
bind substrates [69]. ATP might facilitate the switch
from the closed to the open conformational state [109].
These data may indicate that IDE activity is largely un-
der control of metabolic parameters rather than being
genetically determined.
In the rat brain [110], and in the normal human brain,
IDE was found to be the main soluble Aβ degrading en-
zyme at neutral pH. The highest Aβ degrading activity
occurred between pH 4 and pH 5, indicating that IDE
may act as an “amyloidase“, thus preventing the ac-
cumulation of amyloidogenic derivatives [111], whose
extracellular level is regulated by IDE generated intra-
neuronally [112]. In a physiologic rat cortical cell sys-
tem, IDE was shown to eliminate the neurotoxic effects
of both Aβ1−40 and Aβ1−42 and to prevent the deposi-
tion of Aβ1−40 onto a synthetic amyloid [113]. In con-
trast, inhibition of IDE and IDE-knockouts reduced the
degradation of both amylin, the islet amyloid polypep-
tide in the pancreas [114], and Aβ in the brain, lead-
ing to its accumulation [115]. The interaction between
insulin and the Aβ was demonstrated by the observa-
tion that excess insulin almost completely inhibited the
degradation of both Aβ1−40 and Aβ1−42, while both
Aβ derivatives also inhibited insulin degradation in a
dose-dependent manner [105].
Insulin-like growth factor
IGF-1 has been found to be structurally closely re-
lated to insulin. It exerts pleiotropic effects. IGF-1
peaks during postnatal development only, regulating
glucose metabolism in this period of life, but is barely
detected in the normal adult brain [116,117]. In con-
trast, IGF-1 is generated mainly in the liver [118] and is
found at high levels in circulating blood [119]. IGF-1
may enter the brain via IGF-1 receptors located on both
choroid plexus epithelial cells and on the blood-brain
barrier [120,121]. In the brain, the IGF-1 receptor has
been demonstrated to be widely distributed [82,122]
and homologous to the IR, with nearly identical sig-
nal transduction domains controlling most of the same
intracellular pathways [123,124]. Functionally, circu-
lating IGF-1 has been found to induce neurogenesis
in the adult hippocampus and regulate Aβ levels in
the brain [123,125–127]. As a compensation reaction
to damage, IGF-1 has been demonstrated to be highly
induced in glial cells [128].
Aging is a risk factor
It has been well documented that a multitude of cel-
lular and molecular parameters undergochanges during
lifetime and in the process of normal brain aging [45,
52,129–141]. Beside this multitude of changes of sin-
gle parameters and in context with this article, function-
ally important imbalances of regulative systems may
develop such as:
– energy production (reduced) and energy turnover
(increased);
– insulin action (reduced) and cortisol action (in-
creased);
– acetylcholine action (reduced) and noradrenaline
action (increased) indicative of an increased sym-
pathetic tone;
– formation of ROS (increased) and capacity of their
degradation (reduced);
– loss of membrane lipids and shift of unsaturated
fatty acids in membranes in favor of saturated fatty
acids;
– dysregulation of intracellular pH;
– shift of gene expression profile from the anabolic
site (reduced) to the catabolic site (increased),
to name the functionally most important ones [121,
132].
It is tempting to speculate that these changes/shifts
may indicate consequences of the principle “program-
ming of the brain” [24–27,117] that may be continued
in an uncoupling of synchronization inherently exist-
ing in biological systems [142–144]. This model may
correspond to the age-associated increase in entropy,
which is an elemental, inherent principle of chemical
and biological processes [145–147]. Likewise, in the
physical sciences, the term criticality is used to de-
scribe a self-organized metalabile steady state (meta-
labile equilibrium in entropy). Smaller additional in-
ternal or external events, even ones that are ineffective
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in themselves, may change the biological properties of
the aging brain. Such events may shift a system from
supercriticality to criticality, and finally to subcritical-
ity/catastrophic reaction [148,149], i.e., from a normal
to a disease state in medical terms characteristic of non-
genetic chronic diseases [31] and corresponding to a
complex (non-linear) system. In contrast, the cause-
effect principle may be valid for diseases caused by
genetic abnormalities corresponding to a linear system.
SPORADIC ALZHEIMER DISEASE
Brain glucose metabolism
Early abnormalities were found in reduced cere-
bral glucose metabolism and the appearance of oxida-
tive damage. In 20- to 39-year-old cognitively normal
APOE4-carriers, low rates of glucose metabolism were
found in AD-prone brain regions, such as the posterior
cingulate, the parietal, temporal, and prefrontal cere-
bral cortices, and in the hippocampus. These low rates
were also demonstrated in 50- to 65-year-old cogni-
tively normal subjects homozygous for the E4 allele of
APOE when compared to cognitively normal noncarri-
ers [150,151]. Considering a time interval of 2 years,
the decline of cerebral glucose metabolism was found
to be significantly greater in APOE4-carriers than in
noncarriers [152]. Independent of APOE4 risk, sub-
jects without general cognitive decline (Mini Mental
Status Examination score 25) who progressed to prob-
able sporadic AD showed a 22% reduction of the cere-
bral glucose metabolic rate in the posterior cingulate
cortex [153], whereby the impairment of cerebral glu-
cose metabolism was found to be of predictive signif-
icance [154,155]. These very early occurring abnor-
malities in cerebral glucose metabolism were accom-
panied by oxidative protein damage probably preced-
ing the clinical and morphological manifestations of
the disease [137,156,157].
As sporadic AD progresses, the abnormalities in
cerebral glucose utilization grow more severe [158–
162]. Interestingly, studies performed at the onset of
the disease showed a fall of both blood flow and oxy-
gen consumption of the brain by approximately 20%
only, whereas the metabolic rate of glucose was dimin-
ished by approximately 50%, indicating a marked dis-
proportion of the two metabolic parameters necessary
to form ATP [161,163]. In advanced disease states, the
disproportion between brain oxygen and glucose con-
sumption disappeared,and cerebral blood flow declined
markedly: all parameters run into a final common path
of 30% to 40% of normal values [164].
Intermediary metabolism
The reduced transport of glucose across the blood-
brain barrier (glucose transport protein 1), and from
the extracellular space into neurons (glucose transport
protein 3) [165,166], along with the diminished gly-
colytic glucose breakdown due to the reduced activ-
ity of glycolytic key enzymes [64,167,168], and of
pyruvate dehydrogenase, may be the determinant fac-
tors for the diminution of overall/regional cerebral glu-
cose utilization. As pointed out above [53], the dimin-
ished fructose-6-phosphatemay decrease the formation
of UDP-GlcNAc and thus protein-O-linked beta-N-
acetylglucosamine (O-GlcNAc)-ylation, favoring hy-
perphosphorylation of tau protein (Fig. 3) [169–171].
The diminished generation of acetyl-CoA [55,172–
174] and both the reduced expression of choline acetyl-
transferase [175] and its activity may result in the de-
creased synthesis of acetylcholine in the presynaptic
neuron [129,176]. The reduced function of acetyl-
choline may be strengthened by the increased expres-
sion of acetylcholine esterase [175]. Additionally, the
reduced availability of acetyl-CoA may contribute to
the decreased cholesterol formation in the cholinergic
neurons [57] via the steroid pathway.
In the tricarboxylic acid (TCA) cycle, the activities
of isocitrate dehydrogenase and α-ketoglutarate dehy-
drogenase decreased by 27% and 57%, although the
transcripts of pyruvate dehydrogenase, isocitrate de-
hydrogenase, and α-ketoglutarate dehydrogenase did
not show significant changes [177]. In contrast to the
latter enzyme activities, succinate dehydrogenase and
malate dehydrogenase activities increased by 44% and
54%, respectively [172,178]. In different pathological
conditions such as cerebral ischemia and arterial hy-
poglycemia, the concentration of both succinate and
malate increased, obviously due to increased enzymat-
ic activities in spite of the drastic reduction of other
TCA cycle constituents [179,180]. Such an anaplerotic
reaction may indicate alternative routes in metabolism
to form energy from ketone-bodies in order to reduce
the glucose-born energy deficit [181,182].
Energy metabolism
A functionally most important consequence of the
markedly perturbed glucose metabolism is the decrease
in glucose-derived ATP production,which may damage
ATP-dependent processes of central significance. Ad-
ditionally, ATP deficit has been found to inhibit prote-
olysis [183] and increase the degradation of membrane
736 M. Salkovic-Petrisic et al. / Insulin Resistant Brain State Causes Sporadic Alzheimer’s Disease
Fig. 3. Reduced glucose metabolism alters posttranslational protein modification favoring tau phosphorylation. In the physiological condition
intracellular glucose metabolism via the hexosamine biosynthetic pathway initiates the generation of UDP-N-acetylglucosamine (UDP-GlcNAc),
which is a substrate for N-acetylglucosaminyl transferase (OGT), generating O-N-acetylglycosamine (O-GlcNAc). O-GlcNAcylation of proteins
is proposed to compete with protein phosphorylation on the specific serine/threonine sites in a reciprocal relationship, and O-GlcNAc protein
modification is additionally suggested to be involved in protein degradation, protein-protein interactions, mediation of protein localization,
mediation of transcription, etc. Decreased intraneuronal glucose levels and metabolism lead to decreased O-GlcNAcylation, and consequently to
increased protein phosphorylation, i.e., tau hyperphosphorylation.
lipids [71,184], thus leading to the enhanced generation
of ROS [185]. A few in vivo studies clearly demonstrat-
ed a fall in ATP concentration [186,187]. Studies on
early-onset AD of incipient state (mean age 49y) did not
show any significant reduction (−7%) of ATP as com-
pared to healthy controls. In contrast, in incipient late-
onset sporadic AD (mean age 66y), a 20% reduction
of ATP formation was found, increasing to 35% and to
more than 50% in stably advanced AD (mean age 75y).
Postmortem studies confirmed the progressive fall of
ATP with advancing sporadic AD [175]. However, it
may be assumed that a proportion of the available ATP
is formed from substrates other than glucose [188].
Evidence has been provided that endogenous amino
acids may substitute lacking glucose to form ATP in the
AD brain. Some amino acids have been demonstrated
to be released from the brain in excess, in particular as-
partate and glycine, accompanied by ammonia deriving
from glutamine. The latter is used to form glutamate
which is metabolized in the aspartate aminotransferase
reaction to enter the TCA cycle [189–193] and to be
utilized for ATP formation. The substitution by amino
acids may be assumed to work in incipient disease
states, accompanied by the utilization of endogenous
fatty acids delivered from a pool in brain tissue [194] or
formed from phospholipid catabolism during the initi-
ated neurodegenerative process in sporadic AD [195,
196]. Activation of phospholipase A2 [72,197,198]
and phospholipase C may be started in emergency con-
ditions whereby phospholipase A2 may be disinhibited
by lacking ATP [111]. In neuroglucopenia [199], the
concentration of total free fatty acids increased rapid-
ly 5- to 6-fold in the cerebral cortex, including the
long-chain fatty acids palmitic acid (16:0), stearic acid
(18:0), oleic acid (18:1), arachidonic acid (20:4), and
docosahexenoic acid (22:6), due to the phospholipase-
induced breakdown of phospholipids [197].
INSULIN RESISTANT BRAIN STATE
Induction of an insulin resistant brain state (IRBS)
As speculated above, programming of the brain by
early life events, desynchronization of biological sys-
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tems later in life, and its increasing entropy/declining
criticality may precede IRBS. Several different fac-
tors [85] working in a detrimental concerted action
may initiate an IRBS: cortisol, noradrenaline, and
ROS. A disinhibition of the HPA-axis causes hyper-
cortisolemia with aging [200,201] and in sporadic
AD [202]. Hypercortisolemia may be supplemented
by 11β-hydroxysteroid dehydrogenase I [20,21] to am-
plify glucocorticoid action [203] in the sporadic AD
brain and to increase its risk six-fold. After a 1-min
cold pressure test, both cortisol and noradrenaline in-
creased in sporadic AD patients, indicating HPA-axis
hyperactivity and an increased sympathetic tone sig-
nificantly higher than in age-matched controls [204].
With respect to cortisol response, the same occurred
when low doses of ACTH were applied [205]. Also,
under resting conditions, basal cortisol concentrations
in circulating blood were found to be higher in spo-
radic AD compared with aged-matched controls [12,
206], and cortisol was independently associated with
dementia [207]. In cerebrospinal fluid (CSF), cortisol
levels were found to be markedly increased in sporadic
AD as compared to normal aging [208], which may
cause IR desensitization particularly by inhibition of its
tyrosine residues phosphorylation (Fig. 1) [39,92,96].
With respect to noradrenaline/adrenaline, increased
plasma adrenaline concentration was found in sporadic
AD compared with healthy young and elderly subjects.
Both resting CSF noradrenaline/adrenaline were also
higher in sporadic AD than in young or older healthy
subjects, and increased with dementia severity in spo-
radic AD [209]. The increase of noradrenaline in the
CSF of sporadic AD patients may be due to an in-
creased activity of surviving locus coeruleus neurons,
which is assumed to occur as a compensatory mecha-
nism because of the disease-related loss of noradrener-
gic neurons [210]. The increase of noradrenaline in the
sporadic AD brain, its maintenance in the brain, and
the prolongation of its release after stress [211–213]
may cause an elevation of the cAMP concentration, as
found in the CSF of sporadic AD patients indicating
that the cAMP messenger system is upregulated [214].
B-adrenergic catecholamines decrease the activity of
the receptor’s tyrosine kinase by cAMP-mediated phos-
phorylation of the receptor’s serine/threonine residues
(Fig. 1) [97].
Aside from the aim of this article, it should be no-
ticed that an increase of noradrenaline was associat-
ed with an induction of NFκB-dependent gene expres-
sion [215], and an increase in interleukin-6 in CSF [216,
217]. From these data, it may be tentatively concluded
that an increase in inflammatory capacity is induced by
both glucocorticoid and noradrenaline [218].
Another important age-related phenomenon is ox-
idative stress by the formation of ROS and by caus-
ing oxidative damage [138,184,219–222] along with
an attenuated antioxidant capacity [48,223]. The in-
creased content of ROS, containing the uncharged
species H2O2, may persistently inhibit the activity of
the phosphotyrosine phosphatase, which normally de-
phosphorylates the IR [64,86,89–91]. Thus, inhibition
of IR dephosphorylation may cause receptor ineffec-
tiveness, i.e., functionally, the control of downstream
receptor effects may be severely perturbed (Fig. 1).
Major brain membrane lipids have been found to be
diminished with aging associated with an increase of
free fatty acids in the tissue [224–226]. Elevated con-
centrations of long-chain fatty acids have been shown to
reduce IR binding without involving its tyrosine kinase
activity. Moreover, increased long-chain fatty acids
inhibit the degradation capacity of IDE [227–229].
IRBS and insulin signaling mechanisms
First evidence for the existence of an IRBS was
provided in 1998, when a decrease was found in
both insulin concentration and tyrosine kinase activity,
along with an increase in IR density, in the sporadic
AD brain [230], thus supporting our earlier hypothe-
sis [217]. Subsequent studies [231] showed a marked
reduction of both the expression of insulin and IGF-1
and their respective receptors in different areas of the
AD brain, accompanied by a reduced insulin signal
transduction capacity. When AD was morphologically
staged after Braak and Braak [232], it was shown that
the expression of insulin and IGF-1 and IGF-2 and their
receptors decreased with advancing AD [175]. Most re-
cently [233],no changes in IR proteinα- andβ-subunits
were found in sporadic AD neurons, but their intra-
neuronal site was found to be altered: predominance
at internal and nuclear, and diminution at cytoplasmic
and dendritic sites. The imbalance between increased
IGF-1 receptor levels and its reduced binding capaci-
ty may point to a restricted compensatory capacity in
emergency conditions. Reduced levels of both insulin
receptor substrates (IRS)1 and 2 and abnormalities in
their phosphorylation may indicate compromised in-
sulin signaling, i.e., confirm an IRBS. Interestingly, the
highly significant and progressive disease stage-related
decrease in both IRSs strongly correlated with the in-
creasing neurofibrillary tangle pathology [233]. The
compromised insulin signaling downstream of the IR
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may be mirrored by the activation of protein kinase B
and glycogen synthase kinase-3α/β (GSK-3α/β), the
latter of which was found to accumulate in neurons
probably prior to developing tangles [234–237]. These
abnormalities found at central sites in metabolism may
also indicate a possible sequence of events leading to
the formation of hyperphosphorylated tau-protein and
Aβ (Fig. 1) [73,238].
The inability of insulin to initiate the normal phos-
phorylation cascade at its receptor residues and key
proteins downstream of the IR to regulate the activities
of several second messengers [233,239] may also be
responsible for the severe abnormalities in brain glu-
cose and the related metabolism (see above). Function-
ally, the IRBS may correspond to the pathophysiology
of diabetes mellitus type II. However, in the case of
sporadic AD, we propose the term IRBS instead of “di-
abetes mellitus type II confined to the brain” to avoid
misunderstandings. Also, we share the opinion of other
scientists [240] that both insulin resistance and insulin
deficiency found in the sporadic AD brain may not rep-
resent another type (type 3) of diabetes mellitus [231].
To sum up, the induction of an IRBS may be of pre-
dominating significance for the generation of sporadic
AD.
IRBS CAUSES SPORADIC AD AS A
SELF-PROPAGATING PROCESS
The severe abnormalities in neuronal glucose/energy
metabolism discussed above may be of pivotal signifi-
cance for the emergence of different drastic structural
and functional changes in the sporadic AD brain.
Neurotransmission at the synapse has been demon-
strated to utilize the highest amount of energy among
all other cellular compartments to work sufficiently [72,
241–244]. A major loss of synapses was found in
brain biopsy material in the early stage of sporadic AD,
whereas no neuronal loss could be detected. The num-
ber of plaques and tangles was around half of that found
at autopsy years later [13,14]. Beside synaptic loss, the
reduction in the number of synaptic vesicles may indi-
cate a marked disturbance in synaptic function [245],
pointing to a hindered release of AβPP [246]. In-
terestingly, the reduction of synapse density correlat-
ed better with the degree of dementia symptoms than
did the number of neurofibrillary tangles and neuritic
plaques [247,248], whereas non-demented human be-
ings with profuse tangles and plaques (high pathology
control subjects) did not show synaptic changes [249].
Beside these degenerative processes, compensatory ax-
onal sprouting may also be possible, although to a much
lesser extent than in normal aging [250,251].
An experimentally induced fall in ATP [180,201]
caused severe structural changes in the endoplasmic
reticulum/Golgi apparatus [252]. The persistently and
increasingly existent ATP deficit in the sporadic AD
brain [186,187] may thus vary the structure of the latter
compartments. In both the postmortem sporadic AD
brain and in biopsy specimens of incipient sporadic
AD patients, the areal proportion and the surface area
of the rough endoplasmic reticulum were found to be
reduced and accentuated in tangle-bearing cells [59,
253,254]. The size of the Golgi apparatus was demon-
strated to be smaller by approximately 50%, indicating
a hypometabolic state in general and reduced protein
synthetic activity in particular. Functionally misfolded
proteins may result in proteosomal deficit, which ac-
cumulates in the endoplasmic reticulum/Golgi appara-
tus [65] to represent the state of “endoplasmic reticu-
lum stress” [255]. As an early event in the sporadic
AD nerve cell, atrophy may be a marker of cellular
hypometabolic state as well [256].
The severe abnormalities of the Golgi apparatus co-
incided with a structural and functional impairment of
axons and presynaptic terminals [257–260]. The latter
two ATP-dependent cellular compartments may under-
go disturbances due to insulin signal failure and ATP
deficit. Normally, the mechanochemical protein (mo-
tor)kinesin makes one step (8 nm) per ATP hydroly-
sis and converts energy from the latter into mechan-
ical force to move cellular components along micro-
tubules (rails) [68,261,262]. The latter are stabilized
by tau-protein, ensuring slow axonal transport [263].
Fast axonal transport is performed in vesicular cargoes
moving along microtubules, the way in which AβPP is
transported [264]. In sporadic AD, the activation of the
insulin signal-controlled GSK-3 [51] phosphorylates
kinesin, which is detached from the cargo, resulting in
inhibition of axonal transport [265,266]. Additionally,
tau hyperphosphorylation may jeopardize the normal
binding of tau-protein to axonal microtubules [238],
and may cause its destabilization, resulting in an in-
hibition of axonal flux, including the anterograde traf-
ficking of AβPP. Axons and dendrites were found to be
nearly completely devoid of AβPP, which accumulated
in the cell body [267,268]. The hindered AβPP flux
down the axon was found to degenerate both axons and
synapses [267,268].
It is as yet unresolved whether or not mRNA AβPP
changes in sporadic AD, and if it does, in which direc-
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tion. Reductions of AβPP695 mRNA were reported
to occur in the sporadic AD brain cortex and/or hip-
pocampus [269–274]. In another study, the expression
of the mRNAs of AβPP695, AβPP741, and AβPP770
were found not to be different in the brain cortex of
sporadic AD patients compared with healthy aged sub-
jects [275]. Evidence for increased AβPP mRNA tran-
scripts was presented in pyramidal neurons of different
brain areas such as the hippocampal subfields CA1 and
CA3 [276,277], nucleus basalis of Meynert and locus
coeruleus [278,279], parasubiculum [280], and corti-
cal layers III and V [281]. The inconsistency of these
results may be assumed to have been influenced by the
different methods used, by the different brain regions
studied, as well as by the different degrees of neuronal
loss in chronic dementia states. That regional differ-
ence may be of importance has been demonstrated by
recent findings from the same group. In one study, the
mRNA of AβPP was found to be reduced in the hip-
pocampus and hypothalamus, whereas the mRNA of
tau was increased in both areas [231]. In contrast, in
the anterior frontal cortex, AβPP mRNA was low in the
normal brain but increased with advancing dementia,
whereas tau mRNA showed an inverse pattern [175].
The former abnormalities may be mirrored by in vi-
vo CSF studies of tau protein, Aβ1−40 and Aβ1−42.
An increase of CSF Aβ was observed in the begin-
ning of sporadic AD only, and the correlation between
Aβ and the severity of dementia was found to be neg-
ative [282]. This inversion is maintained during the
course of the disease: the more severe AD becomes,
the more the CSF levels of both Aβ1−40 and Aβ1−42
decline. Otherwise, tau protein increases, and a corre-
lation between tau protein and clinical progression has
been observed [283,284]. Based upon a proportion of
postmortem findings and in vivo CSF data, it cannot
be ruled out that AβPP mRNA is elevated in an earlier
state of the disease in certain brain areas, but decreases
in the course of the disease. In contrast, tau protein
and its phosphorylated derivate may show an inverse
pattern. Taken together, these abnormalities may sup-
port the view that both AβPP and tau protein undergo
remarkable post-translational changes.
Disturbances in insulin signaling [285] and ATP
failure [61–63] may compromise metabolic pro-
cesses in the endoplasmic reticulum/Golgi appara-
tus [252–255,257–260,286]. Cellular energy depletion
has been demonstrated to increase the concentration of
AβPP holoprotein intracellularly, whereas extracellu-
larly both secreted AβPP and Aβ concentrations de-
creased [74]. The transport of AβPP to the plasma
membrane and its release into the extracellular space
may be reduced [246,287–290]. Otherwise, energy
failure caused an increase in both the level and activ-
ity of β-secretase, which is the key rate-limiting en-
zyme for Aβ formation [291] in the endoplasmic reticu-
lum/Golgi apparatus [292–296]. Moreover, the activity
of the ubiquitin-proteasome pathway was found to be
decreased in the sporadic AD brain, resulting in a strik-
ing increase of intracellular Aβ1−40 and Aβ1−42 [297–
300]. Such an intraneuronal accumulation of Aβ 1−42
has been shown in the human AD brain, as well as
the tendency of its aggregation within the cytoplasm of
neurons [301–303].
Evidence has been provided that Aβ accumulation in
the cytoplasm may cause cell lysis, and consequently
form extracellular plaques [304] which are found to be
enriched in brain tissue towards the end of the disease
process [305].
The accumulation of Aβ may point to a reduced ca-
pacity of IDE to degrade this AβPP-derivative. No
pathogenic mutation in the IDE gene has yet been
found [3], and its polymorphisms detected did not show
associations with AD [306–308]. The gene expression
did not show uniform findings. No significant abnor-
malities were found in the hippocampus and hypothala-
mus in one study [147], whereas decreased IDE mRNA
and IDE activity was detected in the hippocampus in
another investigation [309]. In the brains of sporadic
AD patients, different mechanisms may determine the
efficacy of IDE to degrade both Aβ and insulin. The ac-
cumlulation of the former may point to a reduced capac-
ity of IDE to degrade this AβPP-derivative. Otherwise,
different biochemical processes may reduce the degrad-
ing capacity of IDE in general: the increasing concen-
tration of the ROS species H2O2 [106], the reduced ca-
pacity of the insulin signal transduction cascade [102]
(see above), ATP failure [186–188] including a change
in the conformational state of IDE and, thus, its degra-
dation capacity [69,109], and the chronic glucocorti-
coid effect [310] that affects the function of the insulin
receptor (see above) and that has recently been found
to generate an insulin resistant brain state [311]. How-
ever, in neurons adjacent to senile plaques, IDE was
found to be upregulated [312]. The reduced capacity of
IDE (half of that in the control brain [105]) to degrade
its substrates may imply a diminished insulin degra-
dation, which may point to a compensatory response
to the reduced insulin production. However, it may
have to be taken into account that the competition of
IDE for the substrates Aβ and insulin depends on the
Km-value, which, in general, is determined by several
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Table 1
Proposal on the stepwise generation of sporadic AD (from A to D) as a late-life disorder
A) Early-life events (late pregnancy, early postnatal period of unknown duration) may predispose the brain for changes in structure and
function (programming of the brain) as the basis of late-life disorders (gene-environment interaction).
B) With aging (starting between the 6th and 7th decade of life), desynchronization of biological processes may be induced, including the
activity of susceptibility genes (e.g., APOE4), cortisol, noradrenaline, ROS, and membrane function.
C) Increasing entropy/declining criticality may induce an insulin resistant brain state, causing deficits in insulin signal transduction and in
glucose/energy metabolism, resulting in
D) Dysfunction of
– endoplasmic reticulum/Golgi apparatus;
– axonal flow;
– synaptic functioning and assembly;
– membrane constituents (fatty acids, cholesterol);
– cellular clearing of pathological proteins.
The synergism of such mechanism may drive a self-propagating process to finally form hyperphosphorylated tau-protein (neurofibrillary
tangles) and Aβ (neuritic plaques).
intracellular processes. The highest Aβ degrading ca-
pacity of IDE is between pH 4 and pH 5 [111], i.e., the
highest affinity of IDE to the substrate Aβ is at low pH.
Since the affinity of IDE to Aβ has been found to be
low in AD brains [105], no acidic pH may be assumed
in neurons, i.e., in turn, the degrading capacity of IDE
for insulin may, in all possibility, be less severly dis-
turbed as compared to Aβ. Thus it becomes obvious
that several different posttranslation cellular abnormal-
ities contribute to the reduced degradation capacity of
IDE.
UDP-GlcNAc necessary for protein O-glycosylation
is formed from fructose-6-phosphate (see above [53]).
Tau protein has been demonstrated to be modified by
O-GlcNA cylation, hindering tau-protein hyperphos-
phorylation. A deficit in O-GlcNAcylation favors tau
protein (hyper)phosphorylation(Fig. 3) [169,313]. Ad-
ditionally, both ATP and insulin have been demon-
strated to regulate the phosphorylation state of tau-
protein by influencing the activities of phosphorylat-
ing enzymes. A reduction of ATP may activate both
protein kinases erk36 and erk40 [75], causing tau hy-
perphosphorylation [314]. The abnormal work of the
insulin signal transduction cascade increases the activ-
ity of GSK-3 [51], leading to tau protein hyperphos-
phorylation [315,316]. Although hyperphosphorylat-
ed tau protein accumulates in the sporadic AD brain,
the expression of tau protein has been demonstrated to
decrease with advancing AD [232].
CONCLUSION
In conclusion, there is ample evidence that sporadic
AD may be initiated by the induction of an IRBS, which
may take the central role in the causation of cellular
and molecular abnormalities characteristic of sporadic
AD. This self-propagating process may include feed-
back and feed forward interactions (Table 1) among
the work of the synapse, endoplasmic reticulum/Golgi
apparatus, axon, and cell membrane, terminating in the
generation of both hyperphosphorylated tau protein and
Aβ, and their aggregation in neurofibrillary tangles and
neuritic plaques.
In a recent communication, the first evidence was
provided that the intracerebroventricular application of
the diabetogenic substance streptozotocin caused alter-
ations of the rat brain insulin signaling system [317],
although some cognitive deficits [318] and various cel-
lular and molecular abnormalities, including decreased
antioxidative capacity [319], had been previously re-
ported separately and unrelated to the brain insulin sys-
tem, as reviewed by Salkovic-Petrisic et al. [320]. In-
terestingly, in this experimental model the abnormali-
ties were developed as early as 1 month following the
central streptozotocin application and were found to
resemble those seen in sporadic AD [320]. However,
further studies are needed to verify whether or not this
is a consequence of an insulin resistant brain state.
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